Quinta participates at the International Bio-Europe exhibition on 6-8th November, 2017 in CityCube Berlin, Germany.
BIO-Europe is the preeminent partnering conference for the life sciences, bringing together international decision makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities, workshop and panel participation, a high profile exhibition, and private, prescheduled one-to-one meetings.
Delegates from all parts of the biotechnology value chain come to BIO-Europe to quickly identify, engage and enter into strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior BIO-Europe conferences have produced many highly successful business partnerships.
The BIO-Europe 2017 partnering event is expected to draw over 3,800 industry attendees for three days of high level networking, representing upwards of 2,000 companies from over 60 countries.
Partnering as an overall business strategy has transformed drug development in bringing together innovators and visionaries with seasoned experts from every corner of the globe. Partnering at BIO-Europe is powered by EBD Group’s partneringONE, the industry’s most advanced networking system, which enables participants to efficiently mine a large pool of potential partners and pre-arrange private one-to-one meetings with dozens of company targets. The system—industry-specific, web-based and interactive—is uniquely suited for the needs of life science companies.
In addition to the program, two key elements at our partnering events are the presenting companies and the exhibition. At BIO-Europe, presenting companies are grouped into several tracks, including Biotech, Midsize Pharma, Next Generation, and Academic Innovators. The high-exposure exhibition is the heart of the conference, and presents a prime opportunity to showcase products and services in a high-traffic location.
BIO-Europe is produced by EBD Group, the leading partnering firm for the global biotechnology industry, with the support of BIO.
18 July 2023
Challenges of a large-scale study of breast cancer
Our bioanalytical experts and a high-profile client team up for the development of a new therapy for breast cancer.
29 June 2023
EU funding for Quinta-Analytica laboratory in Brno (CZ) was succesfully completed.
After two years, the project to finance new equipment for the Quinta-Analytica laboratory in Brno was successfully completed. The investment from European Regional Development Fund was used in this project.
22 June 2023
Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies
EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency